Results 51 to 60 of about 385 (131)
Cardiomyopathy: pathogenesis and therapeutic interventions
MedComm, Volume 5, Issue 11, November 2024.Cardiomyopathy is a group of diseases characterized by structural and functional damage to the myocardium. Many specific gene mutations, environmental factors, and metabolic disorders may cause cardiomyopathy. Traditional therapeutic includes drug and surgery. With the growing comprehension of the molecular mechanisms underlying cardiomyopathy.
Shitong Huang +9 more
wiley +1 more source
Monaldi Archives for Chest DiseaseHypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder, affecting approximately 1 in 250 individuals. It is defined by unexplained left ventricular (LV) hypertrophy in the absence of other identifiable cardiac or systemic causes.
Carolina Bernardes +3 more
doaj +1 more source
Reviews in Cardiovascular MedicineBackground: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM).
Ali Amr +7 more
doaj +1 more source
European Journal of Heart Failure, Volume 26, Issue 9, Page 1993-1998, September 2024.Aims The aim of this study was to report safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy (nHCM) over 36 weeks in the ongoing FOREST‐HCM trial. Methods and results Patients were started on aficamten 5 mg daily, with doses adjusted in 5‐mg increments (5–20 mg) at ≥2‐week intervals according to site‐read left ...
Ahmad Masri +14 more
wiley +1 more source
Aficamten and Cardiopulmonary Exercise Test Performance
JAMA CardiologyImportance: Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive HCM (SEQUOIA-HCM) is a pivotal study characterizing the treatment effect of aficamten, a next-in-class cardiac ...
Lee, Matthew M. Y. +135 more
openaire +3 more sources
From amoeboid myosin to unique targeted medicines for a genetic cardiac disease
Frontiers in PhysiologyThe importance of fundamental basic research in the quest for much needed clinical treatments is a story that constantly must be retold. Funding of basic science in the USA by the National Institutes of Health and other agencies is provided under the ...
James A. Spudich
doaj +1 more source
ESC Heart FailureAbstract Background/Aims Obstructive HCM (oHCM) affects people across all geographic regions, ethnicities, and socioeconomic groups. In the SEQUOIA-HCM trial (NCT05186818), aficamten, an oral selective cardiac myosin inhibitor, improved exercise capacity, left ventricular outflow gradients ...
Caroline J Coats +21 more
openaire +2 more sources
European Heart JournalAbstract Background and Aims The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations between clinical characteristics and baseline concentrations of N ...
Caroline J Coats +23 more
openaire +4 more sources
Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis
ABSTRACT BACKGROUND Aficamten is a next-in-class, oral, selective cardiac myosin inhibitor approved for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive understanding of long-term safety is essential to inform clinical use.
Ahmad Masri +18 more
openaire +1 more source
The ODYSSEY-HCM and MAPLE-HCM studies: the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy (obstructive and non-obstructive). [PDF]
Eur Heart J SupplBiagini E, Schiavo MA.
europepmc +1 more source